We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
- Authors
Hainsworth, J D; Burris, H A, 3rd; Erland, J B; Thomas, M; Greco, F A
- Abstract
Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2 every 3 weeks. Recent experience with weekly paclitaxel has demonstrated a bone marrow-sparing effect when a weekly administration schedule is used. We investigated a weekly schedule of docetaxel in an attempt to alter the toxicity profile and improve the therapeutic index.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Vol 16, Issue 6, p2164
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1998.16.6.2164